Back to Treatments

Treatment

Alemtuzumab

1
Conditions
46
Trials
1,500
Participants
30%
Average Safety

Condition Evidence

Multiple sclerosis

46 trials · 1,500 participants

93% effectiveness · 30% safety
Alemtuzumab | DFDA